Biotek-snakken — Juli 2020
-
Ja, men køber bestemt ikke anncba's premis om at det burde rykke fordi der er 0% short
-
Sorry - forkert chat
-
Nogle som er bekendt med scandion oncology? Den virker meget attraktiv, og hvis den faldende tendens bliver ved, antager jeg at et muligt entry-point kunne være ved en eventuel support omkring 33-34 SEK. Andre som har haft kig på SCOL?

-
Orphazyme: Euroinvestor/Bioanalytiker har sendt positiv analyse ud på den - Ser betydeligt upside dog one-product company og derfor større risk
-
Det har jeg Bisseminister. Jeg supplerer på faldet.
-
Frimærket bliver så en smule større.
-
Helsinn and MEI Pharma stated Thursday that they have discontinued a Phase III trial testing the experimental oral HDAC inhibitor pracinostat in combination with azacitidine in patients with acute myeloid leukaemia (AML) who are considered unsuitable candidates for standard intensive chemotherapy. The move comes after an interim futility analysis undertaken by the study's independent data monitoring committee indicated that it was unlikely to meet its primary endpoint of overall survivahttps://b
-
How Moderna executives are cashing in on COVID-19 vaccine stock speculationhttps://www.reuters.com/article/us-health-coronavirus-moderna-pay-insigh/how-moderna-execs-are-cashing-in-on-covid-19-vaccine-stock-speculation-idUSKBN2433AH?utm_medium=Social&utm_source=twitter
-
God morgen.

-
Servicemeddelelse: Bemærk at du via vores menulinje kan klikke dig direkte ind på Proinvestors Aktiesnak, Genmab Shareholders, Proinvestors pharma- og bioteksnak og vore Aktiebar på Facebook
-
Tak @radar24
-
Hansa Biopharma har flere skud i bøssen efter EU- anbefaling. https://medwatch.dk/Medicinal___Biotek/article12250737.ece
-
@Helge 3/17 17:13. Har du suppleret op, eller tænker du at den skal yderligere ned? Ser ud til at den ikke brød ned igennem 39. er lidt i tvivl og trenden er vendt, eller hvordan?

-
@Rasbom: Yderligere transplantationsområder (hjerte, lunge, knoglemarv) og autoimun sygdomme (der er ca. 100 forskellige. Der er pt. 2 fase 2 studier igang). Her forventer Hansa selv at gå i markedet. Derudover er der mulighed for partneraftaler indenfor genterapi og onkologi. Så der sidder en hel del fugle på Hansa's tag!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind